Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Incyte Corp (INCY) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Incyte Corp. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 879169.
Total stock buying since 2015: $245,291,742.
Total stock sales since 2015: $378,622,839.
Total stock option exercises since 2015: $101,311,572.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 45,158 | $4,657,827 | 18,668 | $1,147,521 |
| 2025 | 0 | $0 | 417,329 | $38,769,678 | 40,727 | $2,755,585 |
| 2024 | 0 | $0 | 85,339 | $5,534,735 | 33,680 | $1,729,537 |
| 2023 | 0 | $0 | 129,881 | $10,212,029 | 111,519 | $6,144,388 |
| 2022 | 914,884 | $63,635,126 | 108,542 | $8,609,927 | 125,133 | $6,962,110 |
| 2021 | 1,608,444 | $116,033,677 | 82,611 | $6,134,766 | 52,919 | $3,839,651 |
| 2020 | 2 | $205 | 449,346 | $45,550,853 | 490,112 | $28,338,145 |
| 2019 | 0 | $0 | 390,553 | $32,490,379 | 374,907 | $8,303,058 |
| 2018 | 16,000 | $982,865 | 147,276 | $10,140,011 | 181,760 | $3,519,290 |
| 2017 | 103,500 | $13,664,670 | 410,848 | $52,860,791 | 342,250 | $12,759,047 |
| 2016 | 800,000 | $50,975,199 | 166,096 | $15,229,615 | 241,267 | $3,426,425 |
| 2015 | 0 | $0 | 1,511,521 | $148,432,228 | 6,091,040 | $22,386,815 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-09-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-08-13 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 107.69 | 239,287 |
| 2015-08-13 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-08-07 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 8,397 | 18.05 | 151,607 |
| 2015-08-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,936 | 111.95 | 440,635 |
| 2015-08-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,936 | 18.32 | 72,107 |
| 2015-07-15 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 5,000 | 119.75 | 598,750 |
| 2015-07-15 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 5,000 | 17.79 | 88,950 |
| 2015-07-15 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 70,217 | 120.00 | 8,426,040 |
| 2015-07-15 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 70,217 | 17.79 | 1,249,160 |
| 2015-07-14 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 7,850 | 114.75 | 900,787 |
| 2015-07-14 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 7,850 | 14.72 | 115,552 |
| 2015-07-14 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 113.61 | 252,441 |
| 2015-07-14 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-07-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 107.00 | 421,259 |
| 2015-07-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-06-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 11,691 | 108.06 | 1,263,329 |
| 2015-06-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 11,691 | 29.03 | 339,366 |
| 2015-06-19 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 20,000 | 108.13 | 2,162,600 |
| 2015-06-19 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 20,000 | 17.79 | 355,800 |
| 2015-06-12 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,223 | 105.31 | 234,104 |
| 2015-06-12 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,223 | 18.32 | 40,725 |
| 2015-06-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 3,937 | 107.58 | 423,542 |
| 2015-06-08 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 3,937 | 18.32 | 72,125 |
| 2015-05-27 | Friedman Paul A (Director) | Sale | 69,132 | 107.42 | 7,426,505 |
| 2015-05-27 | Friedman Paul A (Director) | Option Ex | 69,132 | 14.72 | 1,017,623 |
| 2015-05-26 | Daly James M (EVP, Chief Commercial Officer) | Sale | 12,093 | 106.22 | 1,284,457 |
| 2015-05-26 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 12,093 | 29.03 | 351,035 |
| 2015-05-26 | Friedman Paul A (Director) | Sale | 127,619 | 107.27 | 13,689,434 |
| 2015-05-26 | Friedman Paul A (Director) | Option Ex | 127,619 | 14.72 | 1,878,551 |
| 2015-05-22 | Friedman Paul A (Director) | Sale | 79,592 | 108.12 | 8,605,327 |
| 2015-05-22 | Friedman Paul A (Director) | Option Ex | 79,592 | 14.72 | 1,171,594 |
| 2015-05-21 | Friedman Paul A (Director) | Sale | 22,651 | 108.83 | 2,465,221 |
| 2015-05-21 | Friedman Paul A (Director) | Option Ex | 22,651 | 14.72 | 333,422 |
| 2015-05-18 | Brooke Paul A (Director) | Option Ex | 20,000 | 7.68 | 153,600 |
| 2015-05-14 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 104.99 | 233,287 |
| 2015-05-14 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-05-11 | Baker Bros. Advisors (gp) Llc (Director) | Option Ex | 60,000 | 7.68 | 460,800 |
| 2015-05-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 7,412 | 99.43 | 736,975 |
| 2015-05-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 7,412 | 18.32 | 135,787 |
| 2015-04-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 36,941 | 107.67 | 3,977,437 |
| 2015-04-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 36,941 | 29.03 | 1,072,323 |
| 2015-04-17 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 7,150 | 102.04 | 729,586 |
| 2015-04-16 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 10,060 | 15.28 | 153,746 |
| 2015-04-14 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 98.72 | 219,355 |
| 2015-04-14 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-04-13 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 14,000 | 96.75 | 1,354,500 |
| 2015-04-13 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 14,000 | 17.79 | 249,060 |
| 2015-04-13 | Swain Paula J (EVP, Human Resources) | Sale | 16,469 | 96.29 | 1,585,800 |
| 2015-04-13 | Swain Paula J (EVP, Human Resources) | Option Ex | 16,469 | 3.11 | 51,218 |
| 2015-04-10 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 9,000 | 92.75 | 834,750 |
| 2015-04-10 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 9,000 | 17.79 | 160,110 |
| 2015-04-07 | Wenqing Yao (EVP, Discovery Medicinal and P) | Sale | 20,031 | 90.16 | 1,805,914 |
| 2015-04-07 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 5,000 | 17.79 | 88,950 |
| 2015-04-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 25,000 | 88.77 | 2,219,250 |
| 2015-04-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-03-30 | Huber Reid M (EVP, Chief Scientific Officer) | Sale | 34,263 | 93.67 | 3,209,483 |
| 2015-03-30 | Huber Reid M (EVP, Chief Scientific Officer) | Option Ex | 34,263 | 18.05 | 618,618 |
| 2015-03-30 | Chardonnet Laurent (Other) | Sale | 113,776 | 93.64 | 10,653,984 |
| 2015-03-30 | Chardonnet Laurent (Other) | Option Ex | 113,776 | 16.04 | 1,825,308 |
| 2015-03-16 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 89.97 | 1,574,475 |
| 2015-03-16 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
| 2015-03-12 | Siegel Eric H. (EVP, General Counsel) | Sale | 2,222 | 89.72 | 199,346 |
| 2015-03-12 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 2,222 | 18.32 | 40,707 |
| 2015-03-12 | Ariko Barry A (Director) | Sale | 80,000 | 89.27 | 7,141,600 |
| 2015-03-12 | Ariko Barry A (Director) | Option Ex | 80,000 | 5.96 | 476,800 |
| 2015-03-10 | Wenqing Yao (EVP, Discovery Medicinal and P) | Option Ex | 4,404 | 18.05 | 79,514 |
| 2015-03-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Sale | 25,000 | 89.91 | 2,247,750 |
| 2015-03-06 | Levy Richard S (EVP, Chief Drug Dev Officer) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-03-05 | Siegel Eric H. (EVP, General Counsel) | Sale | 13,333 | 90.00 | 1,199,970 |
| 2015-03-05 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 13,333 | 18.32 | 244,260 |
| 2015-03-05 | De Schutter Richard U (Director) | Sale | 40,000 | 91.94 | 3,677,400 |
| 2015-03-05 | De Schutter Richard U (Director) | Option Ex | 40,000 | 17.09 | 683,720 |
| 2015-02-25 | Siegel Eric H. (EVP, General Counsel) | Sale | 13,333 | 85.00 | 1,133,305 |
| 2015-02-25 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 13,333 | 18.32 | 244,260 |
| 2015-02-24 | Daly James M (EVP, Chief Commercial Officer) | Sale | 8,334 | 81.77 | 681,471 |
| 2015-02-24 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 8,334 | 16.62 | 138,511 |
| 2015-02-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 2,778 | 83.44 | 231,796 |
| 2015-02-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 2,778 | 18.32 | 50,892 |
| 2015-02-18 | Ariko Barry A (Director) | Sale | 20,000 | 78.43 | 1,568,600 |
| 2015-02-18 | Ariko Barry A (Director) | Option Ex | 20,000 | 7.68 | 153,600 |
| 2015-02-17 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 12,000 | 76.90 | 922,800 |
| 2015-02-17 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 12,000 | 16.25 | 195,060 |
| 2015-02-17 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 76.90 | 1,345,750 |
| 2015-02-17 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
| 2015-02-13 | Friedman Paul A (Director) | Sale | 120,000 | 74.32 | 8,918,400 |
| 2015-02-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 25,000 | 75.11 | 1,877,750 |
| 2015-02-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-01-26 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,042 | 80.00 | 83,360 |
| 2015-01-26 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,042 | 17.79 | 18,537 |
| 2015-01-23 | Daly James M (EVP, Chief Commercial Officer) | Sale | 11,109 | 77.68 | 862,947 |
| 2015-01-23 | Daly James M (EVP, Chief Commercial Officer) | Option Ex | 11,109 | 17.19 | 190,930 |
| 2015-01-23 | Siegel Eric H. (EVP, General Counsel) | Sale | 11,458 | 80.00 | 916,640 |
| 2015-01-23 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 11,458 | 17.79 | 203,837 |
| 2015-01-22 | Siegel Eric H. (EVP, General Counsel) | Sale | 1,042 | 77.99 | 81,265 |
| 2015-01-22 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 1,042 | 17.79 | 18,537 |
| 2015-01-20 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 74.17 | 1,297,975 |
| 2015-01-20 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
| 2015-01-16 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 12,000 | 73.07 | 876,839 |
| 2015-01-16 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 12,000 | 14.72 | 176,640 |
| 2015-01-08 | Siegel Eric H. (EVP, General Counsel) | Sale | 15,626 | 75.00 | 1,171,950 |
| 2015-01-08 | Siegel Eric H. (EVP, General Counsel) | Option Ex | 15,626 | 16.53 | 258,250 |
| 2015-01-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Sale | 25,000 | 71.84 | 1,796,000 |
| 2015-01-06 | Levy Richard S (EVP, Chief Drug Dev&Medical Of) | Option Ex | 25,000 | 18.32 | 458,000 |
| 2015-01-05 | Swain Paula J (EVP, Human Resources) | Sale | 17,500 | 73.90 | 1,293,250 |
| 2015-01-05 | Swain Paula J (EVP, Human Resources) | Option Ex | 17,500 | 3.11 | 54,425 |
Insider trading activities including stock purchases, stock sales, and option exercises of INCY listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Incyte Corp (symbol INCY, CIK number 879169) see the Securities and Exchange Commission (SEC) website.